65,437 trials
Acne Vulgaris
Primary: Absolute Change in Mean Lesion Counts at Week 12 — -18.5; -13.8; -26.9; -16.7 lesion counts
Rheumatoid Arthritis
Primary: The Primary Outcome Measure is the Determination of the Safety and Tolerability of ATI-450 Plus Methotrexate in Patients With Moderate to Severe Rheumatoid Arthritis…
Irritable Bowel Syndrome With Diarrhea
Primary: Change in Stool Form — -0.26; -0.45; -0.49 score on a scale
Plaque Psoriasis
Primary: The Number of Participants With Hypothalmic Pituitary Adrenal Axis Function Suppression as Measured by Cortisol Response Test — 21; 13; 2 Participants
Bradycardia · Arrhythmias
Primary: Incidence of Bradycardia — 0; 0 participants
Depression
Primary: Faux Pas Recognition Test — 0.901; 0.854 score on a scale — p=< 0.05
Urinary Bladder Neoplasm · Neoplasm Metastasis
Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Per Blinded Independent Central Review (BICR) in Patients Whose Tumors Have…
Wound of Skin · Wound Heal
Primary: Change in Wound Diameter — 95.94; 95.94 Centimeters
Substance-Related Disorders
Primary: Average Weekly Change in Morphine Milligram Equivalents (MME) Dispensed — 157.70; 157.81; 103.16; 89.96 Estimated average weekly MME dispensed — p=<0.05
Alcohol Use Disorder
Primary: Percentage of Days Abstinent From Alcohol Use During Treatment as Measured by Timeline Follow Back — 49.26; 53.73; 47.57; 63.25 percentage of days abstinent — p=0.11
Chemotherapy-induced Neutropenia
Primary: Double-Blind Phase: Duration of Severe Neutropenia in Cycle 1 — 1.0; 1.1 days
B Precursor Type Acute Leukemia
Primary: Fat Mass — 5.1; 10.7 percent change in fat mass
GERD
Primary: Change in GERD Symptoms — 0.6; -1.7 units on a scale — p=0.41
Advanced Solid Neoplasm
Primary: Part A: Change From Time-matched Baseline in Fridericia-corrected QT Interval (QTcF) After Pevonedistat Administration — 1.310; -2.231; 3.180; -0.639 milliseconds
Hyperkalemia
Primary: Percentage of Responders — 25; 7 Participants — p=<0.001